Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: Relations of change in bone mineral density, bone markers, and calcium homeostasis

Journal of Rheumatology

Volumn 34, Issue 5, 2007, Pages 1051-1057

  Jacobs, Johannes W G ^a   De Nijs, Ron N J ^a   Lems, Willem F ^b   Geusens, Piet P M M ^g,h   Laan, Roland F J ^c   Huisman, Anne Margriet ^d   Algra, Ale ^a   Buskens, Erik ^a   Hofbauer, Lorenz C ⁱ   Oostveen, Ans C M ^e   Bruyn, George A W ^f   Dijkmans, Ben A C ^b   Bijlsma, Johannes W J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

^e TWENTEBORG HOSPITAL   (Netherlands)

^f MEDICAL CENTER LEEUWARDEN   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h HASSELT UNIVERSITY   (Belgium)

ⁱ PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Alendronate; Alfacalcidol; Bone markers; Bone mineral density; Glucocorticoids; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AMINO TERMINAL TELOPEPTIDE; CALCIUM; GLUCOCORTICOID; OSTEOCALCIN; PARATHYROID HORMONE; PREDNISOLONE; PROCOLLAGEN C PROTEINASE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CHEMICAL ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHEUMATIC DISEASE; STATISTICAL SIGNIFICANCE; URINE;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIUM; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HOMEOSTASIS; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 34248652654     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Task Force on Osteoporosis, American College of Rheumatology. ACR recommendations target prevention and treatment of glucocorticoid-induced osteoporosis. Am Fam Physician 1997;55:1450, 1453.
2. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-503.
3. Royal College of Physicians. Clinical guidelines for the prevention and treatment of osteoporosis. London: Royal College of Physicians; 1999.
4. Pols HA, Wittenberg J. CBO guideline "Osteoporosis" (second revision). Ned Tijdschr Geneeskd 2002;146:1359-69.
5. Geusens PP, de Nijs RN, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004;63:324-5.
6. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24.
7. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
8. Chavassieux PM, Arlot ME, Roux JP, et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000;15:754-62.
9. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 2002;966:73-81.
10. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
11. Sato F, Ouchi Y, Okamoto Y, et al. Effects of vitamin D2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3-E1 osteoblastic cells. Res Exp Med (Berl) 1991;191:235-42.
12. Li M, Healy DR, Simmons HA, Ke HZ, Thompson DD. Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskelet Neuronal Interact 2003;3:39-46.
13. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D(3) analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004;15:589-602.
14. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-84.
15. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1997.
16. Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A. Changes in the RANK ligand/ osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 2006;17:693-703.
17. Abadie EC, Devogealer JP, Ringe JD, et al. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Semin Arthritis Rheum 2005;35:1-4.
18. Lakatos P, Nagy Z, Kiss L, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000;59 Suppl 1:48-52.
19. Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a reexamination of the evidence. J Clin Endocrinol Metab 2002;87:4033-41.
20. Greenspan SL, Holland S, Maitland-Ramsey L, et al. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians 1996;108:230-8.
21. Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001;38:608-23.